A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy

This study has been withdrawn prior to enrollment.
(The 20070201 study was terminated based on evaluation of Palifermin solid tumor data.)
Sponsor:
Collaborator:
Amgen
Information provided by:
Swedish Orphan Biovitrum
ClinicalTrials.gov Identifier:
NCT00540332
First received: October 4, 2007
Last updated: February 27, 2009
Last verified: January 2009
  Purpose

The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin on the incidence of oral mucositis in subjects with locally advanced head and neck cancer receiving postoperative radiotherapy.


Condition Intervention Phase
Head and Neck Cancer
Drug: Placebo
Drug: palifermin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy

Resource links provided by NLM:


Further study details as provided by Swedish Orphan Biovitrum:

Primary Outcome Measures:
  • Incidence of treatment-emergent proteinuria [ Time Frame: 11 weeks ] [ Designated as safety issue: No ]
  • Duration of treatment-emergent proteinuria [ Time Frame: 11 weeks ] [ Designated as safety issue: No ]
  • Incidence of chronic proteinuria [ Time Frame: 11 weeks ] [ Designated as safety issue: No ]
  • Time (days) to onset of treatment-emergent proteinuria [ Time Frame: 11 weeks ] [ Designated as safety issue: No ]
  • Maximum protein-to-creatinine ratio values during the treatment period [ Time Frame: 11 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time [ Time Frame: in Week 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time (days) to onset of severe Oral Mucositis WHO grade 3 or 4 [ Time Frame: 11 weeks ] [ Designated as safety issue: Yes ]
  • Disease status at End of Treatment visit [ Time Frame: 11 weeks ] [ Designated as safety issue: Yes ]
  • Incidence of serum anti-palifermin antibody formation [ Time Frame: 11 weeks ] [ Designated as safety issue: Yes ]
  • Incidence of second primary tumors [ Time Frame: up to 10 years (Long-Term Follow-Up phase) ] [ Designated as safety issue: Yes ]
  • Incidence of other malignancies [ Time Frame: up to 10 years (Long-Term Follow-Up phase) ] [ Designated as safety issue: Yes ]
  • Progression-free survival [ Time Frame: up to 10 years (Long-Term Follow-Up phase) ] [ Designated as safety issue: Yes ]
  • Overall survival [ Time Frame: up to 10 years (Long-Term Follow-Up phase) ] [ Designated as safety issue: Yes ]
  • Incidence of adverse events and laboratory abnormalities [ Time Frame: 11 weeks ] [ Designated as safety issue: Yes ]
  • Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4 [ Time Frame: 11 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: October 2007
Estimated Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo

Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:

  • PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
  • Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects.
Drug: Placebo
Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
Experimental: Palifermin

Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:

  • PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
  • Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects.
Drug: palifermin
120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of newly diagnosed histologically confirmed squamous cell carcinoma (AJCC Stage II, III or IVA) involving either the oral cavity, oropharynx, hypopharynx, larynx and post surgical resection (R0 or R1)
  • Candidates for postoperative RT-only treatment and scheduled to receive RT within 12 weeks of surgery
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
  • Urinary protein-creatinine ratio (random sample, spot PCR) ≤ 0.2 mg/mg

Exclusion Criteria:

  • Tumors of the lips, paranasal sinuses, salivary glands, or of unknown primary tumors and R2 resection margins
  • Metastatic disease (M1)
  • Presence or history of any other primary malignancy, other than curatively treated in situ cervical cancer, or basal cell carcinoma of the skin without evidence of disease for > 3 years
  • History of pancreatitis
  • Prior radiotherapy to the site of disease
  • Prior chemotherapy or requiring chemotherapy during treatment phase of study
  • Prior treatment with palifermin, or other fibroblast or keratinocyte growth factors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00540332

Sponsors and Collaborators
Swedish Orphan Biovitrum
Amgen
Investigators
Study Director: MD Biovitrum AB (publ)
  More Information

Additional Information:
No publications provided

Responsible Party: Clinical Development, Biovitrum AB (publ)
ClinicalTrials.gov Identifier: NCT00540332     History of Changes
Obsolete Identifiers: NCT00965159
Other Study ID Numbers: 20070201
Study First Received: October 4, 2007
Last Updated: February 27, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
United States: Food and Drug Administration
Czech Republic: Statni ustav pro kontrolu leciv
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Swedish Orphan Biovitrum:
Oncology
KGF
HNC
head and neck
oral mucositis
OM
proteinurea
palifermin
clinical trial

Additional relevant MeSH terms:
Head and Neck Neoplasms
Stomatitis
Mucositis
Neoplasms by Site
Neoplasms
Mouth Diseases
Stomatognathic Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 28, 2014